These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35801666)

  • 1. A case of recurrent endometrial cancer with long-term complete remission following pembrolizumab-induced severe immune-related adverse event colitis.
    Yamamoto A; Nagashima T; Imai Y; Akitsu K; Yamanaka Z; Nishi H
    J Obstet Gynaecol Res; 2022 Oct; 48(10):2630-2634. PubMed ID: 35801666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in endometrial cancer.
    Gómez-Raposo C; Merino Salvador M; Aguayo Zamora C; García de Santiago B; Casado Sáenz E
    Crit Rev Oncol Hematol; 2021 May; 161():103306. PubMed ID: 33839243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma.
    Turinetto M; Lombardo V; Pisano C; Musacchio L; Pignata S
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1039-1047. PubMed ID: 36111897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer.
    Chen Y; Huang A; Yang Q; Yu J; Li G
    Front Immunol; 2022; 13():987345. PubMed ID: 36275726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario J; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin J; Choi J; Santin AD
    Ann Oncol; 2021 Aug; 32(8):1045-1046. PubMed ID: 33932502
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
    Galienne M; Rodrigues M
    Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline
    Dizon DS; Dias-Santagata D; Bregar A; Sullivan L; Filipi J; DiTavi E; Miller L; Ellisen L; Birrer M; DelCarmen M
    Oncologist; 2018 Jun; 23(6):650-653. PubMed ID: 29472312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
    Konstantinopoulos PA; Gockley AA; Xiong N; Krasner C; Horowitz N; Campos S; Wright AA; Liu JF; Shea M; Yeku O; Castro C; Polak M; Lee EK; Sawyer H; Bowes B; Moroney J; Cheng SC; Tayob N; Bouberhan S; Spriggs D; Penson RT; Fleming GF; Nucci MR; Matulonis UA
    JAMA Oncol; 2022 Sep; 8(9):1317-1322. PubMed ID: 35900726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
    Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
    Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.
    Kojima M; Soeda S; Okabe C; Sato T; Kamo N; Ueda M; Endo Y; Nomura S; Tokuda E; Furukawa S; Kataoka M; Fujita S; Saji S; Watanabe T; Fujimori K
    Fukushima J Med Sci; 2022 Dec; 68(3):191-195. PubMed ID: 36351631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
    Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
    Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.